Quarterly snapshots from biopharma companies with marketed products, including: Adamas, Astellas, Beigene, Dynavax, Exelixis, Fibrogen, Incyte, Morphosys, Novartis.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Apogenix, Ascletis, Aytu Bioscience, Calidi, Celltrion, Direct Biologics, Edesa, Eisai, Merck, Foresee, Hutchison China Meditech, Poxel, Sumitomo Dainippon, Realta Life Sciences, Relief, Neurorx, Revive, Sound, Takeda, Teva.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: AI, Ampio, Ascentage, Cerecor, Clarity, Cytodyn, Hutchison China Meditech, Immunic, Moderna, Opthea.

Quarterly snapshots from biopharma companies with marketed products, including: Alkermes, Amgen.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Acerus, Affinity, Agenus, Altum, Appili, Avacta, Bergenbio, Betta, Betterlife, Bolt, Celonic, Daewoong, Daiichi Sankyo, Eli Lilly, FSD, G1, Gen1e, Gilead, Grifols, Hansoh, Heat, Humanigen, Hutchison China, Iacta, Immunitybio, Immunome, Immunoprecise Antibodies, Inovio, Intravacc, Johnson & Johnson, Kyorin, Nascent, Neurorx, Neutrolis, Nichi-Iko, Osmotica, Otonomy, Pharmabcine, Piramal Enterprise, Promedica, Qilu, Redhill, Relief, Restorbio, Santen, Schrödinger, Sesen, Simcere, Soligenix, Stemedica Cell, Takeda, Terns, Teva, Theragen, Tscan, Viva, Wuxi Shuangliang.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Cytodyn, Propanc.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Aslan Pharmaceuticals, Neuren Pharmaceuticals.

HONG KONG – California-based Iacta Pharmaceuticals Inc. and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical Ltd. have inked a definitive license agreement for two of Iacta’s products.